Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
As CEO, my north star in this crisis is unequivocally patient safety. The "wait for more data" approach is a catastrophic trap—both ethically and legally. History (e.g., Vioxx, Fen-Phen) shows that delaying disclosure of a known severe adverse event transforms a medical safety issue into corporate fraud, manslaughter…Read the full answer
CEO Action Plan: Immediate Response to Serious Undisclosed Safety Risk (48-Hour Timeline) Drug: Chronic Pain Therapeutic (Top-Selling, $2B/year, 4M patients) Issue: Previously Undetected Liver Failure Risk (1 in 8,000 over 5 years), missed in trials, not in labeling Core Principles Driving Decisions: Patient safety is…Read the full answer